Lupin Q1 FY25 Results Preview: Net profit likely to grow by one-third, margin may improve by 200 bps; here is what else you can expect
Lupin Q1 FY25 Results Preview: Mumbai-headquartered drug maker Lupin is estimated to register a 30 per cent year-on-year jump in its consolidated net profit for the April-June period. Read on to know what else you can expect in the pharmaceutical companys upcoming earnings report.
Lupin Q1 FY25 Results Preview: Mumbai-headquartered pharmaceutical company Lupin is set to report its financial results for the April-June period on Tuesday, August 6. Analysts expect the drug maker to stage a strong financial performance on the back of robust revenue growth across markets amid product launches as well as approvals.
According to Zee Business research, Lupin is estimated to register a consolidated net profit of Rs 590 crore for the quarter ended June 30, which translates to an increase of 30.2 per cent over the corresponding period a year ago. The analysts expect the drug maker's revenue to expand to Rs 5,170 crore for the first quarter of the current financial year, from Rs 4,814 crore a year ago.
The drug maker is estimated to log Rs 1,044 crore in earnings before interest, taxes, depreciation and amortisation (EBITDA) for the June quarter, up 22 per cent on a year-on-year basis, according to the research.
Zee Business analysts peg Lupin's margin - a key measure of profitability - for the fiscal first quarter to come in at 20 per cent as against 18 per cent for the year-ago period. They estimate the pharma firm's revenue from the US and European markets to increase 20 per cent and 25 per cent respectively, and that in the domestic market to grow five per cent.
How Lupin fared in Q4 FY24
Lupin staged a strong performance for the final three months of the financial year 2023-24, with a 52 per cent jump in its consoldiated net profit to Rs 359 crore and revenue growth of 12 per cent to Rs 4,961 crore.
Its margin improved by 710 basis points to 20.1 per cent, according to a regulatory filing.
Lupin Shares: Historical performance
Lupin shares have rewarded investors with a 47 per cent return in 2024 so far, outperforming gains of about 11 per cent and 29 per cent in the Nifty50 and Nifty Pharma indices, respectively.
Catch all the latest stock market updates here. For all other news related to business, market, tech and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.